CorePharma (2)

Executive Summary

CorePharma is a privately-held US pharmaceutical company with a 1998 founding, specializing in high-quality generic and branded oral solid dosage forms. Operating from FDA- and DEA-registered facilities in Middlesex, New Jersey, the company provides end-to-end services from development to commercial manufacturing and packaging. Its focus on oral solid dosage forms positions it well in the large and growing generic drugs market, where demand for cost-effective alternatives continues to drive growth. As a private entity, CorePharma benefits from operational flexibility and ability to target niche therapeutic areas, though financial details are undisclosed. The company's established manufacturing capabilities and regulatory compliance suggest a stable revenue base, but limited public information constrains visibility into growth trajectory. Overall, CorePharma appears as a solid, low-profile player in the generic space, with potential for steady performance rather than explosive upside.

Upcoming Catalysts (preview)

• Q2 2026FDA approval of a high-value abbreviated new drug application (ANDA)60% success
• Q3 2026Strategic partnership or contract manufacturing agreement with larger pharma40% success
• TBDExpansion of manufacturing capacity or new facility launch30% success